Avidity Biosciences (RNA)
(Real Time Quote from BATS)
$46.12 USD
+1.00 (2.22%)
Updated Jul 22, 2024 02:52 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Avidity Biosciences, Inc. (RNA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$61.56 | $96.00 | $45.00 | 36.44% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Avidity Biosciences, Inc. comes to $61.56. The forecasts range from a low of $45.00 to a high of $96.00. The average price target represents an increase of 36.44% from the last closing price of $45.12.
Analyst Price Targets (9 )
Broker Rating
Avidity Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.11 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 88.89% and 11.11% of all recommendations. A month ago, Strong Buy made up 88.89%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RNA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 7 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.11 | 1.11 | 1.11 | 1.13 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/14/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
6/12/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
6/12/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
6/12/2024 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
6/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/11/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/14/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.11 |
ABR (Last week) | 1.11 |
# of Recs in ABR | 9 |
Average Target Price | $61.56 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.76 |